Literature DB >> 25086193

Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases.

Fabio Nascimbeni1, Pascal Lebray2, Larysa Fedchuk2, Claudia P Oliveira3, Mario Reis Alvares-da-Silva4, Anne Varault2, Patrick Ingiliz2, Yen Ngo5, Mercedes de Torres2, Mona Munteanu5, Thierry Poynard2, Vlad Ratziu6.   

Abstract

BACKGROUND & AIMS: Transient elastometry is a noninvasive procedure used to measure fibrosis when patients are diagnosed with liver disease; it might be used to monitor changes over time. We investigated whether there are short-term variations in stiffness measurements that are not attributable to changes in fibrosis by studying patients with stable liver disease.
METHODS: We performed a retrospective analysis of 531 paired liver stiffness measurements made by Fibroscan when the study began (LSM1) and at follow-up (LSM2), more than 1 day and less than 1 year apart, from 432 stable (for body mass index, waist circumference, and alcohol consumption), untreated, immunocompetent patients with chronic liver disease (from January 2006 through March 2009). Variations between the first and follow-up measurements were expressed as absolute (LSM2-LSM1, kPa) or relative ([LSM2-LSM1]/LSM1*100) or as changes in fibrosis stage.
RESULTS: There was >20% variation in 49.7%, >30% in 34.3%, and >50% in 12.2% of paired measurements; this variation was constant across the spectrum of LSM1 values. The variations produced a 1-fibrosis stage difference in 31.5% of pairs and a ≥ 2-stage difference in 9.8% of pairs. Patients with LSM1 >7 kPa had increased probability of having a different stage of fibrosis at LSM2, compared with patients with LSM1 <7 kPa. Factors associated with variation included measurements made by 2 different operators or at least 1 non-senior operator, ratios of interquartile range:median values, significant fibrosis (≥ 7 kPa) at LSM1, baseline body mass index, or a 2-fold difference in level of alanine aminotransferase between measurements. When the analyses were restricted to measurements made by the same operator, the variation was slightly reduced; fibrosis stage differed between measurements for only 34.3% of cases.
CONCLUSIONS: Operator-related and patient-related factors produce significant variations in liver stiffness measurements made by transient elastometry, limiting its use in monitoring patients. These variations are unrelated to disease progression. The lowest levels of variation occur in measurements made in patients with no or early-stage fibrosis or by a single experienced operator.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALT; BMI; Cirrhosis; Disease Progression; Liver Fibrosis Markers

Mesh:

Year:  2014        PMID: 25086193     DOI: 10.1016/j.cgh.2014.07.037

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  20 in total

Review 1.  Critical comparison of elastography methods to assess chronic liver disease.

Authors:  Mireen Friedrich-Rust; Thierry Poynard; Laurent Castera
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

2.  Factors Associated with the Quality of Transient Elastography.

Authors:  Eva Juárez-Hernández; Martha Helena Uribe-Ramos; Martha Helena Ramos-Ostos; Angélica Yanine López-Ramírez; Sofía Ornelas-Arroyo; Juan Luis Romero-Flores; Nahúm Méndez-Sánchez; Misael Uribe; Norberto C Chávez-Tapia
Journal:  Dig Dis Sci       Date:  2015-03-11       Impact factor: 3.199

Review 3.  Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.

Authors:  Michelle T Long; Sanil Gandhi; Rohit Loomba
Journal:  Metabolism       Date:  2020-05-05       Impact factor: 8.694

4.  Myths and mysteries about staging hepatic fibrosis by fibroscan.

Authors:  Raj Vuppalanchi; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2014-11-05       Impact factor: 11.382

5.  Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis.

Authors:  Young Eun Chon; Jun Yong Park; Sung-Min Myoung; Kyu Sik Jung; Beom Kyung Kim; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

6.  Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.

Authors:  Chenxi Liu; Yan Sun; Yao Yang; Yuemin Feng; Xiaoyu Xie; Lingyu Qi; Keke Liu; Ximing Wang; Qiang Zhu; Xinya Zhao
Journal:  Eur Radiol       Date:  2021-02-03       Impact factor: 5.315

7.  Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression.

Authors:  Christopher R Bradley; Eleanor F Cox; Naaventhan Palaniyappan; Susan T Francis; Indra Neil Guha; Guruprasad P Aithal
Journal:  Eur Radiol Exp       Date:  2022-10-24

8.  The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Elliot B Tapper; Tracy Challies; Imad Nasser; Nezam H Afdhal; Michelle Lai
Journal:  Am J Gastroenterol       Date:  2016-03-15       Impact factor: 10.864

Review 9.  Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

Authors:  M Houot; Y Ngo; M Munteanu; S Marque; T Poynard
Journal:  Aliment Pharmacol Ther       Date:  2015-10-30       Impact factor: 8.171

10.  Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.

Authors:  Daniela Cabibi; Fabrizio Bronte; Rossana Porcasi; Sabrina Ingrao; Antonino Giulio Giannone; Marcello Maida; Maria Grazia Bavetta; Salvatore Petta; Vito Di Marco; Vincenza Calvaruso
Journal:  Anal Cell Pathol (Amst)       Date:  2015-11-17       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.